Deep Genomics

There's no publicly available valuation data at this time. As a Series C company in AI Healthcare, the market value remains undetermined.

The investor list includes SoftBank Vision Fund 2, Canada Pension Plan — a mix that reflects confidence in the AI Healthcare business.

A Series C of $180M represents the most recent capital raise in February 2023. The round was led by SoftBank Vision Fund 2.

The team is roughly 100-500 people, headquartered in Canada.

Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research. The company operates in the AI Healthcare sector from Canada.

Brendan Frey established the company in 2015. It's based in Canada. Brendan Frey serves as Founder & Chief Innovation Officer.

There's no public reporting on profitability. With raised $180M in total funding, the company remains at the Series C stage.

Based in Canada 🇨🇦, the company runs its operations in the AI Healthcare space and was established in 2015.